COVID-19 R&D: Pharma’s Path Ahead

Dec 08 2021

• By Andrew Odame-Kwakye

Listen to this article

Global research and development for preventative vaccines and therapeutics to treat COVID-19 have progressed at a rapid pace. Still, key issues remain and to the dampen the effects of virus in 2022, even greater collaboration is needed.

The therapeutic solutions and vaccines developed by the biopharma industry during the pandemic have allowed society to start imagining life after COVID-19. However, more tools and treatments are needed to control the virus. COVID-19 has become a leading cause of death worldwide, and continues to profoundly affect patients, families and societies and strain health care systems.

Three pressing issues stand out and require the collaborative efforts of the biopharma industry to slow the pandemic, reduce deaths...

Big Three Lead From The Front With Medtech Back On Solid Growth Footing

Dec 13 2022

• By Ashley Yeo

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

Infographic: Top 100 Pharma Companies

Dec 13 2022

• By Lucie Ellis-Taitt

The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.

Pfizer Leads An Unusual Year For The Scrip 100

Dec 13 2022

• By Jessica Merrill

Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.

Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down

Dec 12 2022

• By Jo Shorthouse

What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.

Scrip 100: By The Numbers

Dec 06 2023

• By Lucie Ellis-Taitt and Kosh Naran

Pfizer dominated the Scrip 100 rankings of the top pharmaceutical companies in the world based on full year 2022 pharmaceutical sales, driven by its COVID-19 success.